Top

International Urology and Nephrology

Published in:

01-08-2016 | Urology - Original Paper

Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis

Authors: Sung Ryul Shim, Young Joo Cho, In-Soo Shin, Jae Heon Kim

Published in: International Urology and Nephrology | Issue 8/2016

Abstract

Purpose

To investigate the overall treatment efficacy and safety of botulinum toxin type A (BoNTA) injections compared with placebo in interstitial cystitis/bladder pain syndrome (IC/BPS).

Methods

We conducted a systematic review and meta-analysis of the published literature in PubMed, Cochrane Library, and EMBASE on BoNTA use in IC/BPS. Outcome measures included changes of OLS, ICSI, ICPI, VAS, frequency, nocturia, FBC, Qmax, and PVR from baseline and also included adverse events.

Results

A total of five studies were included, with a total sample size of 252 subjects (133 subjects in the experimental group and 119 subjects in the control group). The duration of follow-up ranged from 8 to 12 weeks. The BoNTA dosage was from 50 to 200 U. The pooled overall SMD in the mean change of VAS for the BoNTA group versus the placebo group was −0.49 (95 % CI −0.74, −0.23). There were also significant improvements in ICPI and frequency. The other outcomes (ICSI, nocturia, Qmax, and FBC) were not statistically different between the two groups.

Conclusion

Although BoNTA is not regulatory approved indication, this first evidence-based systematic review and meta-analysis of BoNTA injection for IC/BPS showed significant differences in efficacy of treatment compared with placebo, especially for pain control, and also showed no differences in the rate of procedure-related adverse events.

Hanno P, Dmochowski R (2009) Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn 28(4):274–286. doi:10.1002/nau.20687 CrossRefPubMed

Jhang JF, Kuo HC (2015) Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA injection. Toxins 7(6):2232–2250. doi:10.3390/toxins7062232 CrossRefPubMedPubMedCentral

Hanno PM, Erickson D, Moldwin R, Faraday MM, American Urological A (2015) Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol 193(5):1545–1553. doi:10.1016/j.juro.2015.01.086 CrossRefPubMed

Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, Karsenty G, Schulte-Baukloh H, Schurch B, Wyndaele JJ, European Consensus P (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55(1):100–119. doi:10.1016/j.eururo.2008.09.009 CrossRefPubMed

Chancellor MB, Fowler CJ, Apostolidis A, de Groat WC, Smith CP, Somogyi GT, Aoki KR (2008) Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 5(6):319–328. doi:10.1038/ncpuro1124 PubMedPubMedCentral

Chuang YC, Kuo HC, Chancellor MB (2010) Botulinum toxin for the lower urinary tract. BJU Int 105(8):1046–1058CrossRefPubMed

Jankovic J, Brin MF (1991) Therapeutic uses of botulinum toxin. N Engl J Med 324(17):1186–1194. doi:10.1056/NEJM199104253241707 CrossRefPubMed

Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological A, American Urological A, Society of Urodynamics FPM (2015) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 193(5):1572–1580CrossRefPubMed

Chung SD, Kuo YC, Kuo HC (2012) Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Phys 15(3):197–202

10.

Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M (2006) Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 49(4):704–709. doi:10.1016/j.eururo.2005.12.002 CrossRefPubMed

11.

Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E (2008) Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol 179(3):1031–1034. doi:10.1016/j.juro.2007.10.032 CrossRefPubMed

12.

Kuo HC, Chancellor MB (2009) Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 104(5):657–661. doi:10.1111/j.1464-410X.2009.08495.x CrossRefPubMed

13.

Kuo HC, Jiang YH, Tsai YC, Kuo YC (2015) Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment—a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. doi:10.1002/nau.22760

14.

Shie JH, Liu HT, Wang YS, Kuo HC (2013) Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome. BJU Int 111(4):638–646. doi:10.1111/j.1464-410X.2012.11466.x CrossRefPubMed

15.

Gottsch HP, Miller JL, Yang CC, Berger RE (2011) A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome. Neurourol Urodyn 30(1):93–96. doi:10.1002/nau.20946 CrossRefPubMed

16.

Manning J, Dwyer P, Rosamilia A, Colyvas K, Murray C, Fitzgerald E (2014) A multicentre, prospective, randomised, double-blind study to measure the treatment effectiveness of abobotulinum A (AboBTXA) among women with refractory interstitial cystitis/bladder pain syndrome. Int Urogynecol J 25(5):593–599. doi:10.1007/s00192-013-2267-8 CrossRefPubMed

17.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRefPubMed

18.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 6(7):e1000097. doi:10.1371/journal.pmed.1000097 CrossRefPubMedPubMedCentral

19.

Kasyan G, Pushkar D (2012) Randomized controlled trial for efficacy of botulinum toxin type a in treatment of patients suffering bladder pain syndrome/interstitial cystitis with hunners’ lesions: preliminary results. J Urol 187(4 suppl. 1):e335–e336. doi:10.1016/j.juro.2012.02.912 CrossRef

20.

Chuang YC, Chancellor MB (2006) The application of botulinum toxin in the prostate. The Journal of urology 176(6 Pt 1):2375–2382. doi:10.1016/j.juro.2006.07.127 CrossRefPubMed

21.

da Silva CM, Cruz F (2009) Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it? Curr Opin Urol 19(4):347–352. doi:10.1097/MOU.0b013e32832ae176 CrossRefPubMed

22.

Demidenko E, Sargent J, Onega T (2012) Random effects coefficient of determination for mixed and meta-analysis models. Commun Stat Theory Methods 41(6):953–969. doi:10.1080/03610926.2010.535631 CrossRefPubMedPubMedCentral

23.

Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB (2004) Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 172(4 Pt 1):1529–1532CrossRefPubMed

24.

Rapp DE, Turk KW, Bales GT, Cook SP (2006) Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175(3 Pt 1):1138–1142. doi:10.1016/S0022-5347(05)00322-8 CrossRefPubMed

25.

Chapple C (2014) Chapter 2: pathophysiology of neurogenic detrusor overactivity and the symptom complex of overactive bladder. Neurourol Urodyn 33(Suppl 3):6–13. doi:10.1002/nau.22635 CrossRef

26.

Jankovic J (2004) Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 75(7):951–957CrossRefPubMedPubMedCentral

27.

McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177(3):1071–1077. doi:10.1016/j.juro.2006.10.055 CrossRefPubMed

28.

Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53(6):1236–1244. doi:10.1016/j.eururo.2008.01.075 CrossRefPubMed

29.

Parsons CL, Housley T, Schmidt JD, Lebow D (1994) Treatment of interstitial cystitis with intravesical heparin. Br J Urol 73(5):504–507CrossRefPubMed

30.

Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, Hardy C, Landis JR, Mayer R, Madigan R, Messing EM, Peters K, Theoharides TC, Warren J, Wein AJ, Steers W, Kusek JW, Nyberg LM, Interstitial Cystitis Clinical Trials G (2003) A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol 170(3):810–815. doi:10.1097/01.ju.0000083020.06212.3d CrossRefPubMed

31.

Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, Fowler CJ, Anand P (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urology 174(3):977–982; discussion 982–973. doi:10.1097/01.ju.0000169481.42259.54

32.

Chuang YC, Yoshimura N, Huang CC, Wu M, Chiang PH, Chancellor MB (2009) Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur Urol 56(1):159–166. doi:10.1016/j.eururo.2008.05.007 CrossRefPubMed

33.

Yokoyama O, Miwa Y, Oyama N, Aoki Y, Ito H, Akino H (2007) Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure. J Urol 178(5):2208–2212. doi:10.1016/j.juro.2007.06.044 CrossRefPubMed

34.

Caldwell DM, Ades AE, Higgins JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521):897–900. doi:10.1136/bmj.331.7521.897 CrossRefPubMedPubMedCentral

35.

Ioannidis JP (2009) Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. Can Med Assoc J 181(8):488–493. doi:10.1503/cmaj.081086 CrossRef

Title: Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis
Authors: Sung Ryul Shim
Young Joo Cho
In-Soo Shin
Jae Heon Kim
Publication date: 01-08-2016
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 8/2016
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-016-1295-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2016

Hemophagocytic lymphohistiocytosis: an update for nephrologists

Carbachol-induced signaling through Thr696-phosphorylation of myosin phosphatase-targeting subunit 1 (MYPT1) in rat bladder smooth muscle cells

Effects of feminizing reconstructive surgery on sexual function and genital sensitivity in patients with female pseudohermaphroditism versus healthy control

The application of CT voiding urethrography in the evaluation of urethral stricture associated with fistula: a preliminary report

Aberrant activation of Wnt pathways in arteries associates with vascular calcification in chronic kidney disease

Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials